Merck & Co., Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert Davis
- Full Time Employees
- 74,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 126 East Lincoln Avenue Rahway NJ United States of America 07065
- IPO Date
- Jan 13, 1978
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.
Company News
Merck & Co., Inc. $MRK Stock: Birch Hill Investment Advisors LLC Cuts Holdings
Merck & Co., Inc. $MRK Stock: Baugh & Associates LLC Grows Holdings
If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys
Merck & Co., Inc. $MRK Stock: Banque Pictet & Cie SA Cuts Holdings
Merck Stock: Watch This Price, Prepare To Profit From This Trade
The Stocks That Will Get Investors Home Safe When Tech Cracks
The Big 3: MRK, GILD, XOM
AMGN vs. MRK: Which Pharma Giant's Dividend Actually Has Room to Grow
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Merck & Co., Inc. $MRK Stock: Cliftonlarsonallen Wealth Advisors LLC Cuts Holdings
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
How to Turn $500,000 Into a Lazy $16,500 Yearly Passive Income Stream
Merck & Co., Inc. $MRK Position Cut by Perpetual Ltd
Merck (MRK) Dips More Than Broader Market: What You Should Know
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma ban
Merck & Co., Inc. $MRK Position Increased by NorthCrest Asset Manangement LLC
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
Jefferies cuts Merck's remigromig sales forecast after eye-disease trial raises concerns